Medicamen Biotech Ltd

Medicamen Biotec Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Medicamen Biotech Ltd

₹ 302 -0.61%
29 Sep 4:01 p.m.
medicamen.com BSE: 531146 NSE: MEDICAMEQ
About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Key Points

Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE
  • Market Cap ₹ 410 Cr.
  • Current Price ₹ 302
  • High / Low ₹ 630 / 291
  • Stock P/E 43.2
  • Book Value ₹ 168
  • Dividend Yield 0.33 %
  • ROCE 5.61 %
  • ROE 3.39 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Promoter holding has decreased over last quarter: -2.70%
  • The company has delivered a poor sales growth of 5.31% over past five years.
  • Company has a low return on equity of 5.67% over last 3 years.
  • Earnings include an other income of Rs.6.13 Cr.
  • Dividend payout has been low at 12.7% of profits over last 3 years
  • Company has high debtors of 155 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
33.09 33.53 35.58 38.67 41.94 43.54 46.50 47.32 43.05 44.74 45.14 29.61 43.04
27.43 27.67 29.71 32.18 34.99 38.89 41.60 41.57 39.60 39.43 38.43 31.22 38.43
Operating Profit 5.66 5.86 5.87 6.49 6.95 4.65 4.90 5.75 3.45 5.31 6.71 -1.61 4.61
OPM % 17.10% 17.48% 16.50% 16.78% 16.57% 10.68% 10.54% 12.15% 8.01% 11.87% 14.86% -5.44% 10.71%
0.96 0.52 0.63 0.35 0.38 0.55 0.83 0.57 0.59 0.29 0.14 5.23 0.47
Interest 0.77 0.62 0.68 0.86 0.96 0.91 0.65 1.89 0.71 1.04 0.76 0.65 1.15
Depreciation 1.53 1.62 1.60 1.62 1.69 1.82 1.80 1.77 1.77 2.61 2.21 0.49 1.80
Profit before tax 4.32 4.14 4.22 4.36 4.68 2.47 3.28 2.66 1.56 1.95 3.88 2.48 2.13
Tax % 17.13% 13.04% 10.66% 13.53% 15.81% 39.68% 38.11% 22.93% 48.72% 53.85% 24.74% 25.40% 24.88%
3.59 3.60 3.77 3.77 3.95 1.47 2.03 2.04 0.80 0.91 2.92 1.85 1.60
EPS in Rs 2.94 2.85 2.97 3.07 3.30 1.19 1.90 1.68 1.06 1.15 2.73 1.89 1.59
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
123 125 113 115 141 179 163 163
105 106 93 91 117 156 148 148
Operating Profit 17 20 20 24 24 24 14 15
OPM % 14% 16% 17% 21% 17% 13% 9% 9%
4 2 1 2 2 2 6 6
Interest 1 1 2 2 3 6 4 4
Depreciation 2 2 3 6 6 7 7 7
Profit before tax 18 18 16 18 17 13 10 10
Tax % 31% 26% 26% 18% 14% 27% 34%
12 13 12 15 15 9 7 7
EPS in Rs 10.28 10.88 9.93 12.20 11.73 8.60 5.59 7.36
Dividend Payout % 10% 5% 10% 8% 9% 12% 18%
Compounded Sales Growth
10 Years: %
5 Years: 5%
3 Years: 12%
TTM: -10%
Compounded Profit Growth
10 Years: %
5 Years: -12%
3 Years: -22%
TTM: 28%
Stock Price CAGR
10 Years: 24%
5 Years: -6%
3 Years: -33%
1 Year: -48%
Return on Equity
10 Years: %
5 Years: 7%
3 Years: 6%
Last Year: 3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 12 12 12 13 13 13
Reserves 75 109 121 134 181 194 200
12 11 19 26 26 31 34
38 49 42 53 59 56 50
Total Liabilities 137 181 194 226 279 295 297
24 34 90 92 93 92 87
CWIP 15 40 0 0 0 0 0
Investments 0 0 0 0 0 0 0
97 107 104 133 186 203 210
Total Assets 137 181 194 226 279 295 297

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
4 13 13 4 -6 -7 -8
-15 -37 -18 -8 -6 -6 -1
-4 19 6 4 29 6 -1
Net Cash Flow -14 -5 1 -0 17 -6 -11

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 129 145 170 200 169 112 155
Inventory Days 67 78 27 188 228 234 268
Days Payable 134 173 169 302 241 154 184
Cash Conversion Cycle 62 51 28 86 156 193 239
Working Capital Days 116 130 126 147 156 123 186
ROCE % 16% 13% 12% 10% 8% 6%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 42.99% 42.99% 42.99% 43.16% 40.46%
1.83% 0.17% 0.19% 0.16% 0.22% 0.22% 0.12% 0.06% 0.06% 0.06% 0.12% 0.00%
0.13% 0.20% 0.20% 0.20% 0.20% 0.67% 0.99% 1.17% 1.17% 0.87% 0.69% 0.64%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.06% 0.05%
54.84% 56.42% 56.40% 56.44% 56.38% 55.90% 55.69% 55.78% 55.79% 56.04% 55.99% 58.83%
No. of Shareholders 8,3328,2738,2338,2729,41910,25210,63910,65210,79210,57610,43510,808

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2024
    Transcript
    Notes
    PPT
  • Dec 2021
    Transcript
    Notes
    PPT
  • Nov 2020
    Transcript
    Notes
    PPT
  • Aug 2020
    Transcript
    Notes
    PPT
  • Jun 2020
    Transcript
    Notes
    PPT